Stroke: Relationship between plate plate plate reduction and clinical outcomes in patients with cerebral hemorrhage

The effect of plateplates on hematoma enlargement (HE) in patients with cerebral hemorrhage (ICH) is not yet clear, especially the effect of plate count reduction on HE and clinical outcomes in patients.
recently, a study published in the leading journal in the field of cardiovascular disease,Stroke, looked at the effects of thyroid reduction on HE, functional outcomes, and mortality in ICH patients who received or did not receive antiplateplate therapy (APT).
researchers divided participants into ICH patients who received or did not receive APT based on plateplate counts, who were associated with or were not associated with platet board reduction (plateboard counts - 150×109/L).
51.5% (1124 out of 2183) of all patients used vitamin K antagonists.
researchers used trend scoring matching to address imbalances in baseline characteristics, including the proportion of patients taking vitamin K antagonists.
results analysis included HE (33%) and mortality, as well as functional outcomes measured after 3 months using the improved Rankin scale, which were divided into favorable outcomes (improved Rankin scale score of 0-3) and adverse outcomes (improved Rankin scale score of 4-6).
of the 2,252 ICH patients, 11.4 percent (52 out of 458) and 14.0 percent (242 out of 1725) who received APT experienced plateplate reductions during hospitalization.
of HE patients with or without plateiac reduction were not significantly different among ICH patients who received APT and those who did not receive APT treatment (HE:APT patients: 9 out of 40 patients with thyroid reduction (22.5 per cent) and 27 out of 115 patients with non-thyroid reduction (23.5 per cent), P=0.89; Non-APT patients: 54 out of 174 patients with thyroid reduction, 106 out of 356 patients with thymostyroid reduction,' and 106 of the 356 patients with thyroid reduction (29.8 per cent) and P=0.77.
there was no significant difference in functional outcomes in the (accepted APT and non-accepted APT) tendency scoring matching queues.
There was no difference in mortality after 3 months in patients who did not receive APT, while the mortality rate in APT patients with plate reduction was significantly higher than in patients with APT with normal plateboard count (APT: 29 out of 46 patients with plateiac reduction, 63.0 percent), and 58 out of 140 patients with non-thyroid reduction. 41.4 per cent, P -0.01; non-APT: 95 out of 227 cases of plateiasis, 178 out of 445 patients with non-thymostyroid reduction, 0.49 per cent, P. 0.49).
results, the results showed that platerocyte reduction did not affect the rate and functional outcome of HE in ICH patients, regardless of whether patients were treated with APT.
in view of the increase in mortality, the importance of plateiac infusion to ICH-accompanied plateroid reduction and past APT should be explored in future studies.